NCT04470440View on ClinicalTrials.gov

Thyroid Dysfunction and Nivolumab Reponse in NSCLC

CompletedOBSERVATIONAL
Enrollment

134

Participants

Timeline

Start Date

October 22, 2019

Primary Completion Date

November 5, 2019

Study Completion Date

November 5, 2019

Conditions
Non Small Cell Lung Cancer MetastaticTreatment Adverse EffectThyroid DysfunctionImmune Checkpoint InhibitorPrognosis
Trial Locations (1)

2909

CHRU de Brest, Brest

All Listed Sponsors
lead

University Hospital, Brest

OTHER

NCT04470440 - Thyroid Dysfunction and Nivolumab Reponse in NSCLC | Biotech Hunter | Biotech Hunter